NYSE: $LLY
INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus…
Source: Read More